：心律齐，心率为64次/min，每一个QRS波前都有一个P波（+标记），I、II、aVF和V4-V6导联的P波都为正性。因此，可判断为窦性心律。图中有两种QRS波形。有两个QRS波较窄（*标记），间期正常（0.08s）。他们整体形态还算正常，因为只在II和V1-V3导联看得到这两个QRS波，所以也不确定是否真的正常。这两个

%)。治疗前临床分期在I/II期和III/IV期患者的5年生存率分别为87.5%和14.5%(P=0.001)。治疗前LDH升高者和LDH正常者的5年生存率分别为...KaPlan-Meier法计算生存率,Log-rank法检验差异显著性。结果：全组60例PNET患者中位年龄25岁。其中，I/II期患者18例(30%)，III/IV期

是，ADAM17表达水平较低的II期胃癌患者平均存活时间要长于ADAM17表达水平较高的I期胃癌患者(P < 0.01)。多变量分析表明，ADAM17...上调(P < 0.01)。检测发现，35.78% (156/436)胃癌患者的ADAM17表达水平较高，ADAM17的高水平表达与EMMPRIN的表达水平

，利用冷冻电镜技术解析了人类剪接体复合物两种中间体 pre-C*-I 和 pre-C*-II 结构，整体分辨率高达 3.6 埃。该研究揭示了外显子连接前剪接体复合物 C 到 C* 的转换，增进了人们对外显子连接机制的认识。图片来源：Molecular Cellpre-C*-I 和 pre-C*-II 复合物冷冻电镜结构

被杀在美国十分罕见，但是医疗场所暴力事件在美国却时有发生。美国哈佛大学医学院 James P. Philips M.D. 就美国医疗暴力现状和解决方案发表综述。文章发表在近期出版的 NEJM 上。根据施暴者和工作场所不同，工作场所暴力可分为 4 种类型，医疗场所暴力为 II 型工作场所暴力，也是 II 型

，新增维布妥西单抗（II 级推荐）及维布妥西单抗+纳武利尤单抗（III 级推荐）。在慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的治疗中，对于有 P53 突变的患者...类药物化疗的患者，推荐进入临床试验、CAR-T、R2、IR2、BTK 抑制剂等（II 级推荐）。对于套细胞淋巴瘤（MCL），增加「R-苯达莫司汀/R-大剂量

定义(p<0.0001)。两个治疗组的临床来源的TLR发生率为百分之3.0，而biolimus洗脱支架治疗组的靶血管重建(target vessel...合格，研究者发现，biolimus洗脱支架组节段内晚期丢失为0.03 mm，依维莫司洗脱支架治疗组则为0.06 mm(非劣效性p<0.0001)。NEXT

阿霉素心肌病

官方网站： www.nutritioncare.org/ClinicalNutritionWeek/index.aspx?id=508会议时间：2013/2/9-2013/2/12&nbsp; 地点：美国亚利桑那州凤凰城&nbsp;

大队列、大数据与多组学技术研究突破，革新肿瘤防诊治的全周期，P4 China2018 第三届国际精准医疗大会将于 12 月 1～2 日再度于北京盛大开启！两天三... 1000 元的最优惠价格！联系方式：电话：+86 180 1793 9885邮箱：p4china@bmapglobal.com

ms/440 ms）。每个窄 QRS 波之前均可见 P 波（+），PR 间期恒定（0.36s）。I、II、aVF 以及 V4- V6 导联 P 波正向。因此，考虑为窦性心律伴一度房室传导阻滞。第 2、第 7 个 QRS 波之后的 P 波（*）未下传。PP 间期恒定（72 次/分）。偶然出现的未下传 P 波为二度

<0.001），II类病变组为53.5%（p=0.0003）；2年时复发性闭塞，在III类病变组为64.6%，与之相比I类病变组为15.9%（p<0.001），II类病变组为18.9%（p<0.0001）就此，可以得出结论股髂动脉植入术后再狭窄的分类是支架内再狭窄复发和闭塞的重要预测因子。

了卒中预后评定（SPAN）指数，阳性为：年龄（岁）+NIHSS≥100。他们将SPAN-100指数用于NINDS tPA卒中试验的患者（I期和II期试验...患者的颅内出血发生率较高(42%对比SPAN-100阴性患者的12%; p < 0.001)；同样的，接受tPA治疗的SPAN-100阳性患者的颅内出血

据 Pmlive 于 2018 年 7 月 2 日报道，赛诺菲正在向欧盟申请批准 Cablivi 用于血栓性血小板减少性紫癜（aTTP），这是今年初赛诺菲以 93 亿欧元收购比利时 Ablynx 后获得的重要资产。Cablivi 是第一个被推荐在欧洲批准使用的 aTTP 用药，aTTP 是一种罕见的自身免疫性血液疾病

五一前夕，土豪各种买买买啊，赛诺菲 93 亿美元收购麦迪韦逊，艾伯维 58 亿美元收购 Stemcentrx，最土豪的是雅培制药，今日凌晨正式宣布，已同意以大约 250 亿美元的价格收购医疗设备制造商圣犹达医疗公司（St．Jude Medical），以加强其心脏和神经系统设备业务。北京时间 4 月 28 日晚间路透社

，视力较对照组提高达21个字母。专门针对中国患者设计的为期12个月、多中心临床试验EXTEND II研究验证了雷珠单抗在中国患者中的安全性和有效性， 研究显示，雷珠

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 分子流行病学再揭示人类复杂疾病遗传因素及其与环境因素相互作用发挥重要作用,为人类疾病的风险评估、预防和个性化治疗提供依据。全基因组关联分析（GWAS）为全面系统研究复杂疾病的遗传因素掀开了新的一页，为我们了解人类复杂疾病的发病机制提供了更多的线索。科学家已经在肥胖、糖尿病、冠心病、阿尔茨海默、乳腺癌、前列腺癌、肺癌、胃癌等一系列复杂疾病中进行了全基因组关联研究并找到疾病相关的易感基因，我国科学家也在银屑病、精神病和冠心病等方面开展了GWAS研究并取得成效。国家科技部最新公布了“常见重大疾病全基因组关联分析和药物基因组学研究”的863重点项目，吹响了我国大规模开展GWAS研究的号角。为了让更多的相关研究人员，特别是广大研究生了解GWAS的研究原理和方法，学会设计GWAS的研究和分析实验结果，同时在癌症领域分享海内外研究专家们的成功经验，并期待在GWAS方面进行交流合作,复旦大学和美国Van Andel 研究所将于2009年7月12-14日在上海联合举办上海分子流行病学与GWAS国际 研讨会, 期待各位同道免费参加，请有意者及时将回执返回联系邮箱。免注册费（食宿餐饮费用自理）。名额有限，报名从速！时间： 2009年7月12－14日
报到地点： 复旦大学卿云楼宾馆 上海市邯郸路220号，200433
会议地点： 复旦大学逸夫楼报告厅
联 系 人： 赵雪莹 高歌 联系电话： 021-55664495
回执邮箱： GWAS2009@gmail.com
&nbsp;BackgroundRecent success of genome-wide association studies (GWAS) in the U.S. and Europe has lead to the identification of a large number of genetic variants that are associated with disease risk and progression, including those for cancer and cardiovascular diseases. The discovery of these genetic markers not only improves our understanding of disease etiology, but also contributes significantly to risk prediction, early detection, and targeted treatment of diseases.Although GWAS have been used in Chinese populations to identify Chinese-specific risk-associated genetic variants for several common diseases such as breast cancer and psoriasis, many more GWAS are needed for various diseases. A better understanding of the importance of GWAS and a better knowledge of study design and data analysis of GWAS will further promote broad application of GWAS in China. This symposium which will cover genetic epidemiology and GWAS in China is organized to serve this purpose. We have invited a group of experts in this area from the U.S. and China to share their experience in GWAS, and we hope to foster an environment which will encourage an open discussion among all participants.
Objectives• To better understand the potential applications of GWAS
• To address practical issues in study design, implementation, and data analysis of GWAS
• To promote interaction and collaboration among researchers who are interested in GWAS
• To explore other important studies after GWAS: gene-environment interaction, risk prediction, and functional analyses
• To consider issues and implications related to genomic and personalize medicine
Organizing committeeThe organizing committee consists of four members:
Dr. Jianfeng Xu (Co-Chair)
Dr. Daru Lu (Co-Chair)
Dr. Li Jin (Co-Chair ,Advisor)
Dr. Qingyi Wei (Co-Chair, Advisor)
PresentationsSession I: Genetic epidemiology and GWAS of cancer
• Breast cancer in Chinese populations Xiao-ou Shu
• Genetic association studies of skin cancer Jiali Han
• Genetic variants in the MC1R gene and risk of cutaneous melanoma Qingyi Wei
• Genetic association studies of lung cancer in Chinese populations Daru Lu
• Molecular epidemiology of hepatitis, liver cirrhosis and hepatocarcinoma Gangqiao Zhou
• Molecular epidemiology of stomach cancer Weimin YeSession II: Genetic epidemiology and GWAS of other diseases
• Genetic association studies of hypertension in Chinese populations Jiang He
• GWAS of Autoimmune Diseases (Psoriasis, etc.) in Chinese populations Wei Huang
• Molecular epidemiology of diabetes in Chinese populations Weiping Jia
• Molecular genetics study of hypertension in Chinese populations Dingliang Zhu
• Molecular epidemiology of hepatitis, liver cirrhosis and hepatocarcinoma Gangqiao ZhouSession III: Post-GWAS studies
• Genetic structure of Chinese population Li Jin
• High-throughput genotyping for GWAS and fine mapping studies Siqun Lilly Zheng
• Molecular genetics study of neural tube defect Hongyan Wang
• Risk prediction using genetic variants in prostate cancer Jianfeng Xu
• Gene-environmental interaction in smoking related cancer Zuo-Feng Zhang
• Cancer Somatic Genomics Bin TehSession IV: Short presentations by participants and discussion
Registration时　　间： 2009年7月12－14日
报到地点： 复旦大学卿云楼宾馆大厅 上海市邯郸路220号 (200433)
会议地点： 复旦大学逸夫楼报告厅
联 系 人： 赵雪莹，高歌 (Shanghai, China)；Tamara Adams (U.S.)
联系电话： 21-55664495 (Shanghai, China)；336-713-7532 (U.S.)
回执邮箱： GWAS2009@gmail.com (Shanghai, China)；tsadams@wfubmc.edu (U.S.)
Invited speakers (alphabetic)• Jiali Han, Ph.D., is an Assistant Professor of Medicine at Harvard Medical School. His major research areas are:
• Genetic epidemiology of skin cancer and breast cancer
• Genome-wide association studies
• Gene-environment interaction• Jiang He, M.D. Ph.D., is a Professor and Chair of Epidemiology, Tulane University School of Public Health., U.S.A. His major research areas are:
• Genetic epidemiology of hypertension
• Gene-nutrition interaction of cardiovascular disease• Wei Huang, Ph.D., is a Professor and Executive Deputy Director of Chinese National Human Genome Center at Shanghai, China. Her major research areas are:
• Genetic susceptibility to autoimmune diseases, cardiovascular diseases and cancer.
• Genome-wide association studies
• Genetic variants and association study• Weiping Jia M.D., is a professor of endocrinology at Shanghai Institute of Diabetes, Shanghai No.6 People’s Hospital, Shanghai Jiaotong University, Her major research area is:
• Molecular endocrinology and diabetes• Li Jin, Ph.D, is a Professor of Genetics and vice President of Fudan University, China. His major research areas are:
• Genetic and molecular epidemiology of lung cancer and glioma
• Genetics of metabolism diseases
• Genetic markers for population genetics• Daru Lu, Ph.D, is a Professor of Genetics and Vice Dean of School of Life Sciences, Fudan University, China. His major research areas are:
• Genetic and molecular epidemiology of lung cancer and glioma
• Genetics of metabolic disease• Xiao-ou Shu, M.D, Ph,D, is a Professor of Medicine in the Department of Medicine at the Vanderbilt University School of Medicine, U.S.A. Her major research areas are:
• Genetic and lifestyle predictors of cancer and other chronic diseases
• Cohort study methodology
• Incorporating biomarkers in risk prediction• Bin Teh, M.D, is a Distinguished Scientific Investigator at Van Andel Institute, U.S.A. His major research areas are:
• Translational cancer research
• Gene expression profiling
• Cancer genome high-throughput sequencing• Hongyan Wang, Ph.D, is a professor of genetics at School of Life sciences, Fudan University, China. Her major research area is:
• Molecular genetics and epidemiology of birth defects (deformity of neural tube, congenital heart disease, etc.)• Qingyi Wei, M.D, Ph.D, is a Professor of Epidemiology at The University of Texas M. D. Anderson Cancer Center, U.S.A. His major research areas are:
• Molecular epidemiology of DNA repair, apoptosis, and skin cancer and head and neck cancer
• Genetic susceptibility to cancer
• DNA repair and apoptosis phenotype markers• Jianfeng Xu, M.D, Dr.PH, is a Professor of Epidemiology and Cancer Biology and Director of the Center for Cancer Genomics at Wake Forest University School of Medicine, U.S.A. His major research areas are:
• Genetic epidemiology of prostate cancer
• Genome-wide association and fine mapping analysis
• Risk prediction using genetic markers and other clinicopathologic variables• Zuo-Feng Zhang, M.D., Ph.D, is a Professor of Epidemiology at UCLA School of Public Health, U.S.A. His major research areas are:
• Molecular epidemiology of smoking-related cancers
• Confirmation studies of SNPs identified in genome-wide association studies in smoking-related cancers
• Gene-environmental interaction between genetic markers and environmental factors• S. Lilly Zheng, M.D, is a Professor of Medicine and Director of the Genotyping Laboratory at Wake Forest University School of Medicine. U.S.A. Her major research areas are:
• High-throughput genotyping and sequencing
• Genetic epidemiology of prostate cancer• Gangqiao Zhou, Ph.D, is a Professor of Medical Genetics and Genomics in National Academy of Military Medical Science. His major research area is:
• molecular and genetics of complex diseases• Dingliang Zhu, M.D, is a professor of cardiology at Shanghai Institute of Hypertension, Shanghai, China. His major research area is:
• Molecular and genetics of cardiovascular diseases• Weimin Ye, Ph.D, is a Professor of Medical Epidemiology at Karolinska Institutet, Sweden. His major research areas are: Etiology of upper gastrointestinal diseases
• Topic of presentation: Molecular epidemiology of stomach cancer
&nbsp;

II期临床研究，以及用来支持帕妥珠单抗批准的III期临床试验安全性数据。分析师之前预测帕妥珠单抗的销售额未来五年内可能会达到6亿

复制蛋白保留了更多的自然功能，可减少肌肉细胞破坏的比率。FDA授予Drisapersen突破性治疗药物资格基于四月份报告的由53名患者参与的II期临床研究